{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anal-fissure/prescribing-information/rectal-glyceryl-trinitrate-04percent-ointment/","result":{"pageContext":{"chapter":{"id":"31fddbe9-fb40-54cb-afa9-8ae0b00dccac","slug":"rectal-glyceryl-trinitrate-04percent-ointment","fullItemName":"Rectal glyceryl trinitrate 0.4% ointment","depth":2,"htmlHeader":"<!-- begin field 54bd3eb3-442b-42ba-82e2-fa8e02630d1b --><h2>Rectal glyceryl trinitrate 0.4% ointment</h2><!-- end field 54bd3eb3-442b-42ba-82e2-fa8e02630d1b -->","summary":"","htmlStringContent":"<!-- begin item ebb9e810-7989-4819-8258-b3fb48d382cd --><!-- end item ebb9e810-7989-4819-8258-b3fb48d382cd -->","topic":{"id":"1966ca44-82c6-5654-a1e0-7e73f445ee15","topicId":"28fa6b39-43e9-4444-bb5b-74cb68aa317f","topicName":"Anal fissure","slug":"anal-fissure","lastRevised":"Last revised in January 2017","chapters":[{"id":"5c477a10-68cc-59c7-b721-885d62a44e3f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d9e552-3b6d-544d-b5a8-f71baf5f64ef","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"782501f6-e33e-559b-b516-cc016a798a06","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"464d38ae-bf9a-55c3-a5a8-f26d16c5df49","slug":"changes","fullItemName":"Changes"},{"id":"6d8581b7-e7bc-5ace-9067-e7790612065e","slug":"update","fullItemName":"Update"}]},{"id":"16056078-596d-5ebb-8ccc-9390462b0125","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9864e2c9-5c4d-5bd3-9589-7af84df291ef","slug":"goals","fullItemName":"Goals"},{"id":"ca2ee03c-83a5-5f7a-ae1a-d40584425eca","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5ab7d4c-07ba-584a-85c9-8993560471fa","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"14cb801e-68ae-5549-8b56-f3677a9043c5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edf742df-bebc-5b71-b3e6-1777fa29a00a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"1218c321-dc4c-5239-aba3-919e5633ca24","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"dae58dea-1946-5c28-8542-3f71ab339dee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ae57507c-3884-517d-b28b-b1c7a50c34b5","slug":"definition","fullItemName":"Definition"},{"id":"bbb4426b-3412-53d3-a866-cbcf43067194","slug":"causes","fullItemName":"Causes"},{"id":"81c417d2-aabc-5ba4-8173-a03b78dc8501","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8373fecf-6d3e-5d9e-8a9a-044ee83eb8e9","slug":"prognosis","fullItemName":"Prognosis"},{"id":"d9ea8eda-90ee-570c-b058-9a30e3172b65","slug":"complications","fullItemName":"Complications"}]},{"id":"fedaf0cc-81aa-5cbe-9f52-2aec89f26b4f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ec1128db-c722-548e-a108-2264c18df434","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"419d8e57-b8d9-560b-bc52-564162295c48","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4e5addd6-e78e-58e1-a604-86a9b437edb3","fullItemName":"Management","slug":"management","subChapters":[{"id":"5f1f5405-43b7-5c45-857e-27f84e1df0c6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d6022985-bead-5026-a2e0-c6c3649e7f74","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"31fddbe9-fb40-54cb-afa9-8ae0b00dccac","slug":"rectal-glyceryl-trinitrate-04percent-ointment","fullItemName":"Rectal glyceryl trinitrate 0.4% ointment"}]},{"id":"a992f0d8-4130-5649-aa3c-a0e4b5f32564","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"98daeda4-9027-534c-b84c-5c5f7a081238","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6655ced5-a90b-52c5-be48-e2f87b5f23ef","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1bdadf7-4194-5c80-9368-8ac47ae5f15d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"94472463-588d-5d3f-837a-bb71752d342f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47703418-f019-5d05-9792-b88a2637fd91","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a4a9ca1f-2c32-5e75-b4fb-2490e84d1eb7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2bfa0c27-50a0-596c-8c66-45dd8cde9177","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d6022985-bead-5026-a2e0-c6c3649e7f74","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4ec1671a-0657-578c-8916-2678bcc8902a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 2df5a072-9ea1-4d2a-94a2-bf66e9c50730 --><h3>What are the contraindications and cautions with rectal glyceryl trinitrate ointment?</h3><!-- end field 2df5a072-9ea1-4d2a-94a2-bf66e9c50730 -->","summary":"","htmlStringContent":"<!-- begin item d66f9725-32a7-48e6-a3ee-516f2b68d8ab --><!-- begin field e8180019-582a-4d06-9bdd-4cf3cffbb041 --><ul><li><strong>Do not prescribe rectal glyceryl trinitrate (GTN) 0.4% ointment to:</strong><ul><li>People with:<ul><li>Postural hypotension, hypotension, or uncorrected hypovolaemia — the use of GTN in such states could cause severe hypotension or shock.</li><li>Increased intracranial pressure (for example head trauma or cerebral haemorrhage) or inadequate cerebral circulation.</li><li>Migraine or recurrent headache — there is an increased risk of developing headache with treatment .</li><li>Aortic or mitral stenosis.</li><li>Hypertrophic obstructive cardiomyopathy.</li><li>Constrictive pericarditis or pericardial tamponade.</li><li>Marked anaemia.</li><li>Closed-angle glaucoma.</li></ul></li><li>People younger than 18 years of age — the manufacturer states that rectal GTN 0.4% ointment is not recommended for use in this age group due to a lack of data on safety and efficacy.</li><li>People taking <a class=\"topic-reference internal-reference\" href=\"/topics/anal-fissure/prescribing-information/rectal-glyceryl-trinitrate-04percent-ointment/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>Prescribe rectal GTN 0.4% ointment with caution to:</strong><ul><li>People with:<ul><li>Severe hepatic or renal disease.</li><li>Cardiac disorders (such as acute myocardial infarction or heart failure) — careful clinical and haemodynamic monitoring must be used to avoid hypotension and tachycardia.</li></ul></li><li>Elderly people — they may be more susceptible to the development of postural hypotension. </li><li>Pregnant women — the manufacturer advises against the use of rectal GTN in pregnancy because animal studies are inconclusive about its effects on fetal and postnatal development [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">ABPI Medicines Compendium, 2015</a>]. However, the British National Formulary (BNF) states that it is not known to be harmful during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">BNF 70, 2015</a>].</li><li>Breastfeeding women — the manufacturer advises against the use of rectal GTN in breastfeeding women due to a lack of evidence and potential harmful effects on a breastfed infant. However, the UK Medicines information (UKMi) services states that it is commonly used to treat postpartum anal fissure and is compatible with breastfeeding, but the woman should be advised to [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">UKMi, 2015</a>]:<ul><li>Feed the infant immediately before application of the ointment.</li><li>Try to avoid breastfeeding for 1–2 hours after use.</li><li>Wash her hands immediately after use and before handling the infant.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">ABPI Medicines Compendium, 2015</a>]</p><!-- end field e8180019-582a-4d06-9bdd-4cf3cffbb041 --><!-- end item d66f9725-32a7-48e6-a3ee-516f2b68d8ab -->","subChapters":[]},{"id":"b6ca8cfd-40e9-5a25-b24c-3f4dda633322","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c340996a-3124-4424-ac30-97ed09b8b95c --><h3>What adverse effects are associated with rectal glyceryl trinitrate ointment?</h3><!-- end field c340996a-3124-4424-ac30-97ed09b8b95c -->","summary":"","htmlStringContent":"<!-- begin item e7bf303b-8006-4e36-b622-80ff34dbfc13 --><!-- begin field b9734111-b8d1-4b1e-9e7d-32fa9cd964af --><ul><li><strong>Dose-related headache</strong> is the most common adverse effect, experienced by more than half of all people using rectal glyceryl trinitrate (GTN) 0.4% ointment.<ul><li>In clinical trials of GTN 0.4% rectal ointment, the incidence of mild, moderate, and severe headache was 18%, 25%, and 20% respectively.</li><li>People with a previous history of migraine or recurrent headache are at a higher risk of developing headache during treatment.</li><li>Headache may be experienced after each application and is usually reversible on stopping treatment. It usually responds to treatment with simple analgesics (such as paracetamol and ibuprofen).</li></ul></li><li><strong>Other adverse effects include </strong>dizziness, nausea, and uncommonly, diarrhoea, anal discomfort, vomiting, rectal bleeding, pruritus, anal burning and itching, and tachycardia.</li><li><strong>Rarely, </strong>hypotension may occur, causing dizziness, syncope, and light-headedness. Advise the person:<ul><li>To get up slowly from lying or sitting down to minimize postural hypotension. This is particularly important for people taking diuretics.</li><li>That the hypotensive effects of GTN may be enhanced by alcohol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">ABPI Medicines Compendium, 2015</a>]</p><!-- end field b9734111-b8d1-4b1e-9e7d-32fa9cd964af --><!-- end item e7bf303b-8006-4e36-b622-80ff34dbfc13 -->","subChapters":[]},{"id":"d36e9428-6725-54a6-af55-f7ddb533b8a6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e1e810ed-3580-4a23-83ec-766b915579e0 --><h3>What drug interactions are associated with rectal glyceryl trinitrate ointment?</h3><!-- end field e1e810ed-3580-4a23-83ec-766b915579e0 -->","summary":"","htmlStringContent":"<!-- begin item 1439f28a-5c74-404d-b009-8c24e6204d00 --><!-- begin field df9ac1ee-64c5-4c1b-a2b6-8736be710af0 --><ul><li><strong>Possible drug interactions with </strong><strong>rectal glyceryl trinitrate (GTN) ointment</strong> <strong>include:</strong><ul><li><strong>Phosphodiesterase 5 inhibitors: </strong>concurrent use with sildenafil, tadalafil, and vardenafil is contraindicated as these drugs potentiate the hypotensive effects of GTN.</li><li><strong>Other organic nitrates:</strong> concurrent treatment with other organic nitrates with nitric oxide donors (such as other long-acting GTN products, isosorbide dinitrate, and amyl- or butyl-nitrite) is contraindicated.</li><li><strong>Other vasodilators:</strong> concurrent treatment with other vasodilators (including calcium-channel blockers and angiotensin-converting enzyme [ACE] inhibitors), beta-blockers, diuretics, tricyclic antidepressants, alcohol, and major tranquillizers may potentiate the hypotensive effects of GTN ointment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anal-fissure/references/\">Preston, 2015</a>]</p><!-- end field df9ac1ee-64c5-4c1b-a2b6-8736be710af0 --><!-- end item 1439f28a-5c74-404d-b009-8c24e6204d00 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}